Latest Breaking News On - Florianp thomas - Page 1 : comparemela.com

HNF Launches Groundbreaking 'ABCs of CMT Pain Management' Guide - Brazil Business Today

Pharnext: Findings From 'Real-World' Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease

14.09.2022 - PARIS, FRANCE / ACCESSWIRE / September 14, 2022 / Pharnext SA (FR0011191287:ALPHA) (the Company ), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, . Seite 1

Investegate |Pharnext Announcements | Pharnext: Findings From 'Real-World' Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease

Investegate announcements from Pharnext, Findings From ‘Real-World’ Digital Lifestyle Study, CMT&Me, on Symptom Burden of Charcot-Marie-Tooth Disease Type 1A Published in the Journal of Clinical Neuromuscular Disease

Pharnext Confirms Details for 2021 Hybrid Research & Development Day

Event to be held in person in New York, or virtually via a simultaneous live webcast, on Wednesday October 27, 2021 at 8:30 am ET/ 2:30 pm CETPARIS, FRANCE / ACCESSWIRE / October 21, 2021 / Pharnext SA

Pharnext to Host 2021 Hybrid Research & Development Day